Abstract:Abstract Background Multiple sclerosis (MS) is one of the most common autoimmune disorders characterized by the infiltration of immune cells into the brain and demyelination. The unwanted immunosuppressive side effect of therapeutically successful natalizumab led us to focus on the choroid plexus (CP), a key site for the first wave of immune cell infiltration in experimental autoimmune encephalomyelitis (EAE), for the control of immune cells trafficking. Adenosine A 2A receptor (A 2A R) is emerging as a potential pharmacological target to control EAE pathogenesis. However, the cellular basis for the A 2A R-mediated protection remains undetermined. Methods In the EAE model, we assessed A 2A R expression and leukocyte trafficking determinants in the CP by immunohistochemistry and qPCR analyses. We determined the effect of the A 2A R antagonist KW6002 treatment at days 8–12 or 8–14 post-immunization on T cell infiltration across the CP and EAE pathology. We determined the critical role of the CP-A 2A R on T cell infiltration and EAE pathology by focal knock-down of CP-A 2A R via intracerebroventricular injection of CRE-TAT recombinase into the A 2A R flox/flox mice. In the cultured CP epithelium, we also evaluated the effect of overexpression of A 2A Rs or the A 2A R agonist CGS21680 treatment on the CP permeability and lymphocytes migration. Results We found the specific upregulation of A 2A R in the CP associated with enhanced CP gateway activity peaked at day 12 post-immunization in EAE mice. Furthermore, the KW6002 treatment at days 8–12 or 8–14 post-immunization reduced T cell trafficking across the CP and attenuated EAE pathology. Importantly, focal CP-A 2A R knock-down attenuated the pathogenic infiltration of Th17 + cells across the CP via inhibiting the CCR6–CCL20 axis through NFκB/STAT3 pathway and protected against EAE pathology. Lastly, activation of A 2A R in the cultured epithelium by A 2A R overexpression or CGS21680 treatment increased the permeability of the CP epithelium and facilitated lymphocytes migration. Conclusion These findings define the CP niche as one of the primary sites of A 2A R action, whereby A 2A R antagonists confer protection against EAE pathology. Thus, pharmacological targeting of the CP-A 2A R represents a novel therapeutic strategy for MS by controlling immune cell trafficking across CP.

Comprehensive Analysis of the Immune and Stromal Compartments of the CNS in EAE Mice Reveal Pathways by Which Chloroquine Suppresses Neuroinflammation

Primaquine Elicits Foxp3+ Regulatory T Cells with a Superior Ability to Limit CNS Autoimmune Inflammation

Chloroquine-treated Dendritic Cells Require STAT1 Signaling for Their Tolerogenic Activity

Targeting CB2 receptor as a neuroinflammatory modulator in experimental autoimmune encephalomyelitis

C-Reactive Protein Suppresses the Th17 Response Indirectly by Attenuating the Antigen Presentation Ability of Monocyte Derived Dendritic Cells in Experimental Autoimmune Encephalomyelitis

C16 Peptide Shown to Prevent Leukocyte Infiltration and Alleviate Detrimental Inflammation in Acute Allergic Encephalomyelitis Model

Drug repurposing of ilepcimide that ameliorates experimental autoimmune encephalomyelitis via restricting inflammatory response and oxidative stress

Immunoregulation of Experimental Autoimmune Encephalomyelitis by the Selective CB1 Receptor Antagonist.

Drug repurposing of ilepcimide that ameliorates experimental autoimmune encephalomyelitis <i>via</i> restricting inflammatory response and oxidative stress

Clozapine reduces infiltration into the CNS by targeting migration in experimental autoimmune encephalomyelitis

2-Bromo-1,4-Naphthalenedione promotes CD8+ T cell expansion and limits Th1/Th17 to mitigate experimental autoimmune encephalomyelitis

Complement tunes glutamate release and supports synaptic impairments in an animal model of multiple sclerosis

Quercetin regulates dendritic cell activation by targeting STAT4 in the treatment of experimental autoimmune encephalomyelitis

Inhibiting the NLRP3 Inflammasome with MCC950 Alleviates Neurological Impairment in the Brain of EAE Mice.

Matrine suppresses expression of adhesion molecules and chemokines as a mechanism underlying its therapeutic effect in CNS autoimmunity

C-Phycocyanin ameliorates experimental autoimmune encephalomyelitis and induces regulatory T cells

Curcumin ameliorates experimental autoimmune encephalomyelitis in a C57BL/6 mouse model

Immune Characteristics Study of AG490, a Signal Pathway Inhibitor, in EAE Model Mice

Choroid plexus-selective inactivation of adenosine A2A receptors protects against T cell infiltration and experimental autoimmune encephalomyelitis

Targeted Immunomodulation of Inflammatory Monocytes Across the Blood-Brain Barrier by Curcumin-Loaded Nanoparticles Delays the Progression of Experimental Autoimmune Encephalomyelitis

CXCL12 (SDF-1α) suppresses ongoing experimental autoimmune encephalomyelitis by selecting antigen-specific regulatory T cells